Pulmonary Research

Pulmonary Studies Accepting Participants

Adults

COPD

Chiesi

Study Number: CCD-0599AA3-02—A 6-week, multi-center, randomized, double-blind, placebo-and active-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of 4 doses of CHF 5259 pMDI (HFA Glycopyrronium Bromide via Pressurized Metered Dose Inhaler) in subjects with chronic obstructive pulmonary disease (COPD).

Study Info 

Principal Investigator(s): Stephen Ryan, MD 

Study Coordinator: Jami Roland, [email protected], 253-403-0389

---

TRELEGY

Study Number: GSK 207609 - A Phase IV, 12-week, randomised, double-blind, triple dummy study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) with multiple inhaler therapy (budesonide/formoterol plus tiotropium) based on lung function and symptoms in participants with chronic obstructive pulmonary disease

Study Info

Principal Investigator(s): Stephen Ryan, MD 

Study Coordinator: Jami Roland, [email protected], 253-403-0389

---

BOREAS

Study Number: SANOFI EFC15804—A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) with Type 2 inflammation

Study Info 

Principal Investigator(s): Stephen Ryan, MD 

Study Coordinator: Jami Roland, [email protected], 253-403-0389

---

AIRWISE

Study Number: 1237-0064—The AIRWISE Study: Assessment In a Real World setting of the effect of Inhaled Steroid-based triple therapy versus the combination of tiotropium and olodaterol on reducing COPD Exacerbations

Study Info 

Principal Investigator(s): Stephen Ryan, MD 

Study Coordinator: Jami Roland, [email protected], 253-403-0389

Asthma

PT001102

Study Number: PT001102 - A randomized, double-blind, parallel group, multicenter, 24-week study comparing the efficacy and safety of three doses of PT001 to placebo and open label Spiriva Respimat.

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Roland, [email protected], 253-403-0389

---

CHRONICLE

Study Number: D3250R00023 - A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Roland, [email protected], 253-403-0389

---

GB001

Study Number: GB001-2001 - A Phase 2b, randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 as maintenance therapy in adult subjects with moderate to severe asthma

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Roland, [email protected], 253-403-0389

---

HO-18-18558

Study Number: HO-18-18558 - Asthma Control in Pulmonary and Allergy Clinics in the United States

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Roland, [email protected], 253-403-0389

Influenza A

Emergent FLU

Study Number: IA-001 - A randomized, double-blind, placebo-controlled, dose-ranging study evaluating the safety, pharmacokinetics and clinical benefit of FLUIGIV in hospitalized patients with serious Influenza A infection.

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Juanita Baker, [email protected], 253-403-0366

Non-Cystic Fibrosis Bronchiectasis

The Willow Study

Study Number: INS1007-201 - A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, tolerability and pharmacokinetics of INS1007 administered once daily for 24 weeks in subjects with non-cystic fibrosis bronchiectasis.

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Juanita Baker, [email protected], 253-403-0366

Idiopathic Pulmonary Fibrosis

SPIRIT

Study Number: BIOGEN 203PF203 - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Roland, [email protected], 253-403-0389

---

BOEHRINGER INGELHEIM

Study Number: BOEHRINGER INGELHEIM 1199-0324 - Study of Pulmonary Rehabilitation In Nintedanib Treated Patients with IPF: Improvements in Activity, Exercise Endurance Time, and QoL

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Roland, [email protected], 253-403-0389

Pulmonary Sarcoidosis

NDS-CP-001

Study Number: NDS-CP-001 - A multicenter, open-label study to estimate the effect sizes of HRCT endpoints in response to Glucocorticoid induction therapy in subjects with pulmonary sarcoidosis.

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Roland, [email protected], 253-403-0389

Chronic Cough

MERCK MK-7264-030

Study Number: MERCK MK-7264-030 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough (PN030)

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Roland, [email protected], 253-403-0389

Pediatrics

Idiopathic Bilateral Cataracts

CTX Prevalence Study

Study Number: 018CTXX15001—An observational, multi-center study of the prevalence of cerebrotendinous Xanthomatosis (CTX) in patient populations diagnosed with early-onset idiopathic bilateral cataracts.

Study Info

Principal Investigator(s): Michael Raff, MD

Study Coordinator: Dalia Sherif, [email protected], 253-403-2698

RSV

MK-1654-002

Study Number: MK-1654-002—A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants

Study Info

Principal Investigator(s): Timothy Murphy, MD

Study Coordinator: Karyna Boykin, [email protected], 253-403-9349